Sign In
Buy QGEN
$36.45
+0.760 (+2.13%)
At Close: Jun 03, 2026
QIAGEN expands QIAcuity digital PCR offering with over new 100 assays via GeneGlobe platform
04:05pm, Wednesday, 18'th Sep 2024
QIAGEN adds over 100 new validated QIAcuity digital PCR assays for cancer research, inherited genetic disorders, infectious disease surveillance, and other applications // QIAcuity digital PCR enables
QGEN Stock Likely to Gain From Innovation Amid Competition
12:11pm, Tuesday, 17'th Sep 2024
To support internal growth, QIAGEN invests heavily in research and development for the menu expansion of its key platforms.
Can QGEN Stock Gain From the Expanded Bio-Manguinhos/Fiocruz Alliance?
11:10am, Friday, 13'th Sep 2024
QIAGEN and Bio-Manguinhos/Fiocruz team up to enhance malaria and dengue detection in Brazil's national screening programs.
QIAGEN and Bio-Manguinhos/Fiocruz collaborate to enhance malaria and dengue detection in Brazil's national screening programs
04:05pm, Thursday, 12'th Sep 2024
Advanced PCR-based screening platform deployed nationwide across 30 laboratories provides new capabilities to detect malaria, HIV, HCV, and HBV in blood donations // Advanced capabilities support epid
QIAGEN Stock Likely to Gain on Collaboration for APOE Genotyping
10:20am, Thursday, 05'th Sep 2024
QGEN collaborates with Eli Lilly to develop a QIAstat-Dx IVD panel for APOE genotyping.
QIAGEN to develop the first QIAstat-Dx IVD panel for neurodegenerative applications // New QIAstat-Dx panel to identify APOE genotypes, one of many factors considered in the diagnosis of patients with
QIAGEN N.V. announces conversion price of new net share settled convertible bonds
05:05pm, Tuesday, 03'rd Sep 2024
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION
QIAGEN N.V. announces successful placement of new net share settled convertible bonds
11:00am, Tuesday, 03'rd Sep 2024
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION
QIAGEN N.V. launches non-US offering of net share settled convertible bonds
02:36am, Tuesday, 03'rd Sep 2024
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION
Why Is Qiagen (QGEN) Down 0.3% Since Last Earnings Report?
12:36pm, Friday, 30'th Aug 2024
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?
QIAGEN and AstraZeneca Expand Pact to Develop CDx in Chronic Diseases
09:25am, Friday, 30'th Aug 2024
QGEN's expanded collaboration with AstraZeneca to focus on developing companion diagnostics beyond oncology.
QIAGEN expands QIAstat-Dx into precision medicine through partnership for companion diagnostics in chronic diseases
04:05pm, Wednesday, 28'th Aug 2024
New agreement expands collaboration with AstraZeneca beyond oncology, including complex chronic diseases // QIAGEN's syndromic testing platform QIAstat-Dx enables specialty care providers to make fast
Reasons to Retain QIAGEN Stock in Your Portfolio Now
10:55am, Tuesday, 27'th Aug 2024
Investors remain optimistic about QGEN due to its progress in test menu expansion and impressive prospects within its molecular diagnostics segments.
Why Qiagen (QGEN) is a Top Momentum Stock for the Long-Term
10:55am, Thursday, 22'nd Aug 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Qiagen (QGEN) is a Strong Momentum Stock
10:55am, Monday, 05'th Aug 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
